Fastest
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →https://www.patsnap.com/resources/blog/rd-blog/raman-process-monitoring-signal-processing-patent-landscape/ · Patsnap · data cut-off 2026-07-31 · downloaded from the live page
Patent Landscape · Raman Process Monitoring Signal ProcessingRaman process monitoring signal processing patents: who holds the ground and where it is still open
- 16.6% concentration at the top. The five leading assignees combined account for 123 of the 739 records in scope — a meaningful cluster, but not a lock on the field.
- Filing growth has cooled, not collapsed. Filings moved from 55 in 2021 to 47 in 2024, a -15% shift over that span, after peaking at 64 in 2019.
- Optical and AI classes are still thin. G02B optics sits at 4.2% of records and G06N computing-based methods at 10.4%, both far behind the 99.6% base rate for G01N analysis claims.
739
Published Records
17%
Top-5 Share of All Records
-15%
Filing Growth 2021→2024
US
Leading Jurisdiction
Filing growth compares 2021 (55 records) with 2024 (47) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 739 records in scope (CR5), not by the ranked leaders only.
Published byPatsnap Research··8 min readSourced from Patsnap Eureka
Overview
What this landscape covers
This dataset tracks 739 published records at the intersection of Raman spectroscopy hardware and the signal-processing steps that make it usable for process monitoring: baseline correction, noise filtering, peak resolution, spectral derivatives, normalization and feature selection, scoped to G01N21/65, C12Q3/00 and G01N21/359. It spans filings from 2015 through the 2026 data cut-off, though the most recent one to two years are still filling in as publications catch up with filing dates.
The picture that emerges is a field anchored by a handful of established filers in biomedical and semiconductor-adjacent applications, with a long tail of single- or few-filing entrants working on narrower signal-processing angles. Family-level counts, rather than raw document counts, are used throughout so that continuation practice and multi-jurisdiction filing do not distort the ranking.
Filing activity and technology composition, 2015–2026
Source: Patsnap Eureka. Assignee ranking and totals. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
10,000 free credits to start
The Numbers
Filing trends and technology composition
Two views of the same 739-record set: how filing activity has moved year over year, and which IPC subclasses the records fall into.
Filing activity, 2017–2026
Filings held at 22 in both 2017 and the partial-year 2026, with a peak of 64 in 2019. The 2021-to-2024 span, the last window with complete publication data, moved from 55 to 47 filings, a -15% change — a cooling in pace rather than a reversal, since 2025-onward figures are still understated by publication lag.
Technology composition by IPC subclass
G01N material analysis carries 99.6% of records, effectively the scope definition itself. Behind it, G01J light measurement (33.6%) and A61B diagnosis/surgery (15.0%) show where Raman signal processing is actually being applied, while G06N AI-based computing (10.4%), C12Q enzyme/DNA testing (6.2%), G02B optics (4.2%), G16H healthcare informatics (2.8%) and C07K peptide chemistry (2.7%) mark the smaller, more specialised branches. Because records can carry multiple classes, these shares add up to more than 100% of the 739 records.
Shares are the percentage of the 739 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Source: Patsnap Eureka. Filing trend and technology composition. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.
Go deeper on Raman Process Monitoring Signal Processing with Eureka
This page is one run against one query. Ask Eureka your own question about raman process monitoring signal processing and every answer comes back with the patent numbers behind it.
Try EurekaKey Patents
Representative and most-cited filings
Representative Filing
Raman spectroscopy system and methods of using the same
BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
The filing describes a Raman spectroscopy system built around a tissue probe fitted into a thin sheath adapted for any flexible or rigid laryngoscope. Its signal collection system spans roughly 200 cm-1 to 4000 cm-1, combining a probe, laser source, excitation and collection filters, a charge-coupled-device detector, and a computer/display stack into one clinically deployable unit.Filed by Board of Supervisors of Louisiana State University and Agricultural and Mechanical College, published 2024-07-11 as US20240225451A1.
Most-cited records in this dataset
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20060034729A1 | Optical sensor with layered plasmon structure for enhanced detection of chemical groups by SERS | 181 |
| 2 | US9554738B1 | Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using coll… | 178 |
| 3 | US20160097716A1 | Systems and methods for blood glucose and other analyte detection and measurement using collision computing | 166 |
| 4 | US20080076985A1 | Raman Spectral Analysis Of Sub-Surface Tissues And Fluids | 97 |
| 5 | US6313423B1 | Application of Raman spectroscopy to identification and sorting of post-consumer plastics for recycling | 97 |
| 6 | US7351588B2 | Optical sensor with layered plasmon structure for enhanced detection of chemical groups by SERS | 95 |
| 7 | US20180299375A1 | Fluid analysis and monitoring using optical spectroscopy | 75 |
| 8 | US6867858B2 | Raman spectroscopy crystallization analysis method | 74 |
| 9 | US20120123688A1 | Raman spectroscopy for bioprocess operations | 62 |
| 10 | WO2006061565A1 | Raman spectral analysis of sub-surface tissues and fluids | 62 |
Citation counts are drawn from within this searched corpus and favour older filings; treat them as a signal of influence on the field rather than of current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Source: Patsnap Eureka. Citation counts and representative records. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Run it yourself
Put your own technology through the same analysis
Where to run it
For builders
MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →Insights
What the data means for a filing decision
Three patterns stand out once the raw counts are put next to each other: where claim density already sits, where growth has actually gone, and where citation weight is concentrated.
Concentration
16.6%
top 5 of 739 records
The top of the field is not a monopoly
The five leading assignees together hold 16.6% of the 739 records in scope, rising to 25.7% for the ten leading assignees. That leaves the large majority of filings spread across a long tail of organisations with a handful of records each — room to compete, provided a filing targets a specific signal-processing step rather than the broad Raman-monitoring concept.
Based on the full 100-company ranking returned for this dataset.
Momentum
-15%
2021 to 2024 filings
Growth has cooled from its 2019 peak
Filings peaked at 64 in 2019 and by the last fully-published year, 2024, had settled at 47, down from 55 in 2021. That is a cooling of pace, not a collapse — and because publication lags filing by around 18 months, the 2025–2026 figures in the trend line are still incomplete and should not be read as a further decline.
2021–2024 is the most recent complete comparison window.
Application mix
15.0%
A61B diagnosis & surgery share
Clinical and analytical applications dominate the class mix
Beyond the near-universal G01N analysis classification, A61B diagnosis-and-surgery claims sit at 15.0% of the 739 records, well ahead of the smaller healthcare-informatics (G16H, 2.8%) and peptide-chemistry (C07K, 2.7%) branches. That gap signals where the signal-processing methods are being reduced to specific clinical or diagnostic instruments rather than left as general-purpose spectroscopy claims.
Class shares sum above 100% because records carry multiple IPC codes.
Eureka AI Agent
Looking for what nobody has claimed yet?
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to raman process monitoring signal processing, with the prior art for and against each one.
Co-filing is rare in this field
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Dow Silicones Corp | Hemlock Semiconductor Corporation | 11 |
| The Science and Technology Facilities Council | PARKER ANTHONY WILLIAM | 2 |
| The Science and Technology Facilities Council | MATOUSEK PAVEL | 2 |
| VP Holdings LLC | POPONIN VLADIMIR | 2 |
| THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK | ADVANCED CYTOMETRY INSTR SYST LLC | 2 |
| The Science and Technology Facilities Council | Agilent Technologies UK Limited | 1 |
| Genentech Inc | Roche Diagnostics | 1 |
| Dow Silicones Corp | PINET MARC | 1 |
Only 10 co-assignee pairs appear across the dataset, and the strongest pairing links two industrial semiconductor-materials filers rather than a broader collaboration network — most organisations here are filing independently.
Source: Patsnap Eureka. Co-assignee relationships and derived observations. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Players
Who is active, and where the gate sits
The ranked leaders account for a real but limited share of total filings, and recent-year momentum data shows several of the historically active names dropping to zero filings in the latest year — consistent with the broader cooling in filing pace rather than any single company's retreat.
Leader
35
records
A single assignee holds the top position
The leading assignee's 35 records put it well ahead of fifth place (17) and tenth place (11), but even that lead only represents a fraction of the 739-record field. No organisation here holds anything close to a majority position.
Ranking is by patent family count.
Mid-field
17 → 11
fifth to tenth place
The drop-off past the leader is gradual
Records fall from 17 at fifth place to 11 at tenth, a gentler slope than the gap between first and second place implies. That gradual curve is where most of the practically achievable competitive positioning sits.
Top 10 combined hold 25.7% of all 739 records.
Momentum
0
latest-year filings, several leaders
Several historically active filers show zero recent filings
Recent-year momentum tracking shows multiple assignees that were active earlier in the dataset recording zero filings in the latest year, including year-over-year drops of -100% for some. This tracks with the broader 2021–2024 cooling rather than signalling an exit from the field, given publication lag on the newest filings.
Momentum figures reflect publication dates, which lag filing by roughly 18 months.
Recent-year filing momentum by assignee
| Assignee | Recent year | YoY |
|---|---|---|
| Cell Therapy Catapult | 0 | — |
| Regeneron Pharmaceuticals Inc | 0 | -100% |
| The Science and Technology Facilities Council | 0 | — |
| Amgen Inc | 0 | -100% |
| VP Holdings LLC | 0 | — |
| Zyomed Hldg Inc | 0 | — |
| Genentech Inc | 0 | -100% |
| THE RES FOUNDATION FOR THE STATE UNIV OF NEW YORK | 0 | -100% |
Source: Patsnap Eureka. Assignee-level momentum. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
What's Next
Where to take this next
The landscape numbers point to specific next steps depending on whether the goal is freedom-to-operate, portfolio strategy, or spotting a filing gap.
Check freedom-to-operate against the cited core
The most-cited records in this dataset, several dating back over a decade, still define the baseline optical and signal-processing architecture that newer filings build on. Any new filing in Raman-based analyte detection should be checked against that cited core before drafting claims.
Run a freedom-to-operate check in EurekaMap the under-claimed branches in detail
G02B optics and G16H informatics both sit under 5% of the 739 records despite being natural extensions of Raman process monitoring. A deeper claim-by-claim review of those branches would clarify how much genuine white space remains.
Explore white space with EurekaWatch the leader's next filings closely
With the top assignee holding 35 records against a fifth-place figure of 17, its next filings will likely set the direction for the rest of the field's mid-tier competitors.
Track assignee activity in EurekaSource: Patsnap Eureka. Forward-looking reading of the same dataset. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
FAQ
Common questions about this landscape
The dataset ranks 100 companies by family count, with the leading assignee holding 35 records, fifth place at 17 and tenth place at 11. The top five combined account for 16.6% of all 739 records in scope, and the top ten for 25.7%, which means the field has a visible leader but no single dominant controller. Most of the remaining filings are spread across a long tail of organisations with only a few records each, so competitive analysis needs to look well beyond the top names.
Filings peaked at 64 in 2019 and by 2024, the most recent year with complete publication data, had settled at 47, down from 55 in 2021 — a -15% change over that span. This looks like a cooling in pace rather than an active decline, and because publication typically lags filing by around 18 months, the apparent flatness in 2025 and 2026 figures is partly an artifact of incomplete data rather than a real drop. Anyone assessing momentum should treat the last one to two years of any trend line as provisional.
Optical elements and systems (G02B) appear in only 4.2% of the 739 records, and healthcare informatics (G16H) in just 2.8%, both far behind the near-universal G01N material-analysis base and the 33.6% G01J light-measurement share. That gap suggests narrower opportunities in portable optics for signal collection, informatics integration for diagnostic Raman output, and feature-selection methods tailored to enzyme or DNA assays, where claim density is currently thin relative to the core spectroscopy methods.
With the top five assignees holding 16.6% of the 739 records and the top ten holding 25.7%, concentration here is moderate rather than extreme — a recognisable leader exists, but roughly three-quarters of filings sit outside the ten most active organisations. Co-filing is also rare in this dataset, with only 10 co-assignee pairs identified, indicating that most participants are developing and filing independently rather than through joint ventures or shared research programmes.
US20240225451A1, filed by the Board of Supervisors of Louisiana State University and Agricultural and Mechanical College and published in mid-2024, describes a Raman spectroscopy system built into a thin sheath for laryngoscope-mounted tissue probing, combining a laser source, excitation and collection filters, a CCD detector and a signal-processing and display stack across a roughly 200 to 4000 cm-1 collection range. It illustrates how recent filings tend to bundle general Raman signal-processing steps into a specific clinical instrument form factor rather than claiming the processing method in the abstract.
Answers are grounded in the same dataset. Derived from a Patsnap search on Raman Process Monitoring Signal Processing covering 2015–2026, data cut-off 2026-07-31. Counts reflect published records only and shift as new filings publish.Run this in Eureka MCP
Research Raman Process Monitoring Signal Processing in depth with Eureka
Go past this page: query the whole raman process monitoring signal processing corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company's registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.